We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
KEYTRUDA Merck Sharp & Dohme (Australia) Pty Ltd
Product name
KEYTRUDA
Accepted date
Jul-2024
Active ingredients
pembrolizumab
Proposed indication
For the treatment of recurrent locally advanced or metastatic Merkel cell carcinoma.
Application type
C (new indication)
Publication date
Jul-2024